How to Use Ipamorelin: Administration, Reconstitution & Storage (2026)
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
How to Use / Administration Methods
Ipamorelin is administered via subcutaneous injection, typically into the abdominal fat, thigh, or deltoid region.
Injection process:
Reconstitute the lyophilized powder with bacteriostatic water
Draw the appropriate dose into an insulin syringe (typically 29-31 gauge)
Pinch a fold of skin at the injection site
Insert the needle at a 45-90 degree angle
Slowly depress the plunger
Withdraw and dispose of the needle properly
Injection sites should be rotated to prevent lipodystrophy or tissue irritation. Most users find subcutaneous abdominal injections the most convenient and least painful option.
Reconstitution, Storage & Prep
Ipamorelin typically arrives as a lyophilized (freeze-dried) powder requiring reconstitution before use.
Reconstitution Process:
Allow the peptide vial to reach room temperature
Using a sterile syringe, draw the desired amount of bacteriostatic water (typically 2-3 mL per 5 mg vial)
Inject the water slowly against the vial wall, allowing it to run down gently
Swirl gently, never shake, until the powder is fully dissolved
The solution should be clear and colorless
Dosing Calculation Example:
If reconstituting 5 mg with 5 mL bacteriostatic water, the concentration equals 1 mg/mL or 1000 mcg/mL. For a 200 mcg dose, draw 0.2 mL (20 units on a standard insulin syringe).
Storage Guidelines:
Unreconstituted powder: Store at room temperature or refrigerated; stable for 12+ months
Reconstituted solution: Refrigerate at 2-8°C (36-46°F); use within 4-6 weeks
Never freeze reconstituted peptides
Protect from light and heat
Use bacteriostatic water (not sterile water) for multi-dose vials to prevent bacterial growth
Frequently Asked Questions
Initial effects on sleep quality may be noticed within the first week. Measurable changes in body composition typically require 8-12 weeks of consistent use, with optimal results appearing after 12-16 weeks.
While some users employ extended protocols, cycling (12-16 weeks on, 4-8 weeks off) is generally recommended to maintain receptor sensitivity and pituitary responsiveness. Long-term safety data in humans is limited.
Unreconstituted powder is stable at room temperature but benefits from refrigeration. Once reconstituted with bacteriostatic water, it must be refrigerated and used within 4-6 weeks.
Yes, ipamorelin is used by both men and women at similar doses. Women may particularly benefit from its collagen-enhancing and anti-aging properties.
Yes, administering ipamorelin at least 30 minutes before eating or 2+ hours after meals optimizes GH release, as elevated insulin blunts the response.
There is no direct evidence linking ipamorelin to cancer development. However, growth hormone and IGF-1 can theoretically promote growth of existing malignancies, so individuals with active cancer or high cancer risk should avoid GH-elevating compounds.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561.
Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113.
Svensson J, et al. Effects of growth hormone secretagogues on bone. Endocrine. 2001;14(1):63-66.
Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus. Journal of Gastrointestinal Surgery. 2008;12(7):1223-1231.
Ghigo E, et al. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460.
World Anti-Doping Agency. Prohibited List.
Kojima M, Kangawa K. Ghrelin: structure and function. Physiological Reviews. 2005;85(2):495-522.
U.S. Food and Drug Administration.
Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Annals of Internal Medicine. 2008;149(9):601-611.